Moreover, EBV-associated diseases, and consequently each EBV-positive malignancy is clearly defined by the set of expressed genes that characterize one of three latency programs: Burkitt‘s lymphoma has a type I latency pattern (EBER+, LMP1-, and EBNA2-); Hodgkin lymphoma and a variety of non-Hodgkin lymphomas have a type II pattern (EBER+, LMP1+, and EBNA2-); and post-transplant lymphoproliferative disorders (PTLD) that develop in an immunocompromised host most often have the type III latency pattern (EBER+, LMP1+, and EBNA2+) [20]. The gene discussed is PDLIM7; the disease is non-Hodgkin lymphoma.